Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients
Completed
Guerbet
Phase 4
2002-05-01
The objective of this study is to characterize the safety, efficacy and pharmacokinetic
profiles of Optimark at the standard clinical dose of 0.1 mmol/kg in the pediatric patient
population.
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients
Completed
Mallinckrodt
Phase 4
2002-05-01
The objective of this study is to characterize the safety, efficacy and pharmacokinetic
profiles of Optimark at the standard clinical dose of 0.1 mmol/kg in the pediatric patient
population.
Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies
Completed
Astellas Pharma US, Inc.
N/A
2014-05-16
This is a pilot study in a patient population with suspected coronary artery disease (CAD) as
defined by the presence of a prior abnormal nuclear (PET/SPECT) myocardial perfusion scan. In
this study design, PET/SPECT will serve as the comparative standard for presence of
myocardial ischemia. We intend to determine the accuracy of an improved magnetic resonance
imaging (MRI) technique for detection of myocardial ischemia in subjects with suspected CAD.
This is not a study to specifically evaluate the efficacy or safety of the drugs but rather
the diagnostic performance of the improved cardiac MRI procedure.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.